All In Biotech

Drug Trial Radar · NCT02656485

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray

Last checked: Nov 19, 2026Latest source record: Apr 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Aug 5, 2015

Primary completion

Mar 1, 2016

Study completion Jul 15, 2016

Sponsor

Lead sponsor
AOBiome LLCIndustry
Sponsor type
Industry
First posted
Jan 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single center, randomized, double-blind, placebo-controlled study in subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • B244Drug

    10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

  • PlaceboDrug

    10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Number of Participants With Treatment Related Adverse Events)Time frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stephens Associates

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.